Changing the level of some serum proteins in patients with breast cancer on the background of treatment therapy

The purpose of the study was to assess changes in the level of lactoferrin and ferritin in perimenopausal patients receiving trekrezan during the course of basic chemotherapy for breast cancer.

Material and methods. To study the concentration of serum lactoferritin and ferritin in breast cancer, the object of the study was patients aged 45 to 55 years, the average age was 50.7 ± 2.6 years. All patients of the main group (n =49) used basic chemotherapy in combination with trekrezan (hydroxyethylammonium methylphenoxyacetate) at a dose of 600 mg/day for 4 weeks. Comparison group patients (n = 45) received only chemotherapy. All patients (before and after a course of chemotherapy) in the blood were determined by biochemical and general indicators of blood.

The results of the study. It was established that the use of trekrezan in addition to basic chemotherapy, contributed to an increase in the concentration of lactoferrin in patients of the main group — from 396.32 ± 24.82 to 4069.32 ± 114.06 ng/ml and ferritin — from 26,2 ± 1.8 ng/ml to 439.47 ± 16.3 ng/ml, in comparison with patients of the other group. At the same time, the indicators of total protein, urea, hemoglobin, red blood cells, white blood cells and blood lymphocytes normalized in the blood in the main group of patients.

Conclusion. Against the background of the use of trekrezan, normalization of the indicators of lactoferrin and ferritin in patients of the perimenopausal period receiving chemotherapy for breast cancer is observed, which indicates a positive effect of this drug on the patient’s immune status.